We specialize in accelerating drug discovery and development through innovative chemistry solutions. Our late-stage functionalization platform is a cornerstone of our integrated Research Chemistry Platform and Chemistry Technology Platform, enabling precise modifications of complex molecules at advanced stages of synthesis. This approach reduces development timelines, enhances molecular diversity, and optimizes lead compounds for clinical success. By focusing on late-stage transformations, we empower pharmaceutical partners to refine drug candidates with minimal risk and maximal efficiency.
Overview of Late-Stage Functionalization Platform
Late-stage functionalization (LSF) refers to the strategic introduction of functional groups into complex molecules—such as active pharmaceutical ingredients (APIs), intermediates, or natural products—after their core structures have been synthesized. Unlike early-stage modifications, LSF allows targeted diversification without requiring de novo synthesis, preserving valuable intermediates and reducing resource expenditure. Our platform integrates cutting-edge technologies to perform selective C–H bond activations, cross-couplings, and heteroatom incorporations, even on sterically hindered or sensitive substrates. This capability is critical for optimizing pharmacokinetics, improving solubility, or introducing isotopes for tracer studies. By leveraging LSF, we address key challenges in drug development, including intellectual property expansion, metabolite profiling, and late-stage lead optimization.
Our Services
Custom Late-Stage Molecular Diversification
We tailor functionalization strategies to meet specific project goals, whether introducing halogens for radiolabeling, adding polar groups to enhance solubility, or incorporating bioisosteres to improve target affinity. Our team evaluates substrate compatibility, reaction feasibility, and scalability to deliver gram-to-kilogram quantities of modified compounds.
Scaffold Optimization for Lead Series
For clients with validated lead compounds, we refine core scaffolds through regioselective modifications. This includes methyl/ethyl group additions, fluorinations, or stereochemical adjustments to boost efficacy or mitigate toxicity. Our workflows are designed to retain critical pharmacophores while exploring structure-activity relationships (SAR).
Our Technologies
- C–H Activation and Functionalization Technologies
Using transition metal catalysts (e.g., Pd, Ru), we selectively modify inert C–H bonds in aromatic or aliphatic systems. This avoids pre-functionalization steps, saving time and reducing waste.
- Photoredox Catalysis Technologies
Light-driven reactions enable radical-based functionalizations under mild conditions, ideal for electron-rich or photolabile substrates. Applications include trifluoromethylations and alkynylations.
- Biocatalysis Technologies
Enzymatic methods provide enantioselective modifications, such as hydroxylations or amine couplings, with high specificity. This is particularly valuable for chiral API derivatives.
- Electrochemical Synthesis Technologies
Electrochemistry facilitates redox-neutral transformations without stoichiometric oxidants/reductants. We employ this for decarboxylative couplings or heterocycle functionalization.
Frequently Asked Questions
Q1: How does late-stage functionalization reduce drug development costs?
LSF eliminates the need to re-synthesize molecules from earlier stages, preserving time and resources. By modifying existing intermediates, clients avoid redundant steps in route scouting and validation, accelerating IND-enabling studies.
Q2: Can your platform handle highly complex or sensitive molecules?
Yes. Our technologies, such as photoredox and biocatalysis, operate under mild conditions to prevent substrate degradation. Prior computational modeling ensures compatibility, while real-time analytics monitor reaction progress.
Q3: Can you support isotope labeling for preclinical studies?
Absolutely. We specialize in site-specific incorporation of stable isotopes (e.g., deuterium, carbon-13) using catalytic deuteration or cross-coupling strategies, aiding ADME studies and patent protection.